Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company’s patent application number 17/387,845, titled, “Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”
The drug discovery and development firm said included within this application are several drug candidates that it classifies as belonging to its ‘Family 1’, which are second-generation compounds with potential improvements compared to psilocybin in pharmacokinetics, effect size, safety, and manufacturing.
“This notice of allowance marks yet another important milestone in our pursuit of creating next generation psychedelic drugs to treat neurological and psychiatric disorders with unmet needs,” Mindset Pharma CEO James Lanthier said in a statement.
READ: Mindset Pharma progresses plans for clinical trials of its advanced pre-clinical psychedelic MSP-1014
“This is a key step towards continued growth for Mindset and our developing pipeline of drug candidates,” Lanthier added.
Mindset Pharma noted that the patent carries a priority date of February 4, 2020.
Mindset Pharma is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
Contact Sean at sean@proactiveinvestors.com